HomeCompareVRPX vs PM

VRPX vs PM: Dividend Comparison 2026

VRPX yields 500000.00% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VRPX wins by $4.663521010693878e+33M in total portfolio value
10 years
VRPX
VRPX
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.663521010693878e+33M
Annual income
$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00
Full VRPX calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — VRPX vs PM

📍 VRPX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVRPXPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VRPX + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VRPX pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRPX
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, VRPX beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRPX + PM for your $10,000?

VRPX: 50%PM: 50%
100% PM50/50100% VRPX
Portfolio after 10yr
$2.331760505346939e+33M
Annual income
$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

VRPX
Analyst Ratings
1
Hold
Consensus: Hold
Price Target
$3.00
+749900.0% upside vs current
Range: $3.00 — $3.00
Altman Z
-90.8
Piotroski
0/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRPX buys
0
PM buys
5
PoliticianChamberTickerTypeAmountDate
Julia Letlow🏢 House$PM▼ Sell$1,001 - $15,0002026-02-05
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$PM▼ Sell$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$PM▼ Sell$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$PM▲ Buy$1,001 - $15,0002025-09-29
Ro Khanna🏢 House$PM▲ Buy$15,001 - $50,0002025-09-05
Ro Khanna🏢 House$PM▲ Buy$15,001 - $50,0002025-08-26
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-08-14
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-07-22
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVRPXPM
Forward yield500000.00%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$4.663521010693878e+33M$49.6K
Annual income after 10y$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$2,502.61
Total dividends collected$4.6634009849658873e+33M$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$3.00$194.30

Year-by-year: VRPX vs PM ($10,000, DRIP)

YearVRPX PortfolioVRPX Income/yrPM PortfolioPM Income/yrGap
1← crossover$50,010,700$50,000,000.00$11,650$409.56+$50.00MVRPX
2$233,748,371,262$233,694,859,813.08$13,592$497.49+$233748.36MVRPX
3$1,021,074,511,412,696$1,020,824,400,655,446.10$15,882$605.21+$1021074511.40MVRPX
4$4,168,597,328,794,951,700$4,167,504,779,067,739,000.00$18,589$737.41+$4168597328794.93MVRPX
5$15,905,475,114,600,665,000,000$15,901,014,715,458,854,000,000.00$21,794$899.94+$15905475114600664.00MVRPX
6$56,718,938,532,531,060,000,000,000$56,701,919,674,158,435,000,000,000.00$25,597$1,100.16+$56718938532531060736.00MVRPX
7$189,031,807,435,623,860,000,000,000,000$188,971,118,171,394,040,000,000,000,000.00$30,118$1,347.30+$1.8903180743562385e+23MVRPX
8$588,799,810,476,518,260,000,000,000,000,000$588,597,546,442,562,100,000,000,000,000,000.00$35,505$1,652.97+$5.8879981047651824e+26MVRPX
9$1,714,064,268,114,722,600,000,000,000,000,000,000$1,713,434,252,317,512,700,000,000,000,000,000,000.00$41,940$2,031.88+$1.7140642681147225e+30MVRPX
10$4,663,521,010,693,878,300,000,000,000,000,000,000,000$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$49,643$2,502.61+$4.663521010693878e+33MVRPX

VRPX vs PM: Complete Analysis 2026

VRPXStock

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Full VRPX Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this VRPX vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRPX vs SCHDVRPX vs JEPIVRPX vs OVRPX vs KOVRPX vs MAINVRPX vs MOVRPX vs BTIVRPX vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.